undamentalytics Newsletter
Sign in

Edgewell Personal Care Co (EPC) stock

Add to watchlist

Add holding +

NYSE: EPC NYSE Personal Care Products Next results ~November 12, 2026

C+ Fundamentals grade

Edgewell Personal Care Co is a US-listed company in the personal care products industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$25

Valuation models combined (6)

Base case. Range ~$12–$45. Weighted average of 6 models (growth cash-flow model, forward price-to-earnings vs peers, residual income, justified price-to-book, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Edgewell Personal Care Co valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds101 adding, 107 cuttingOf 36 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Edgewell Personal Care files

Where Edgewell Personal Care Co stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.24bn, up 11.6% on a year earlier, faster than the 6.5% growth a quarter earlier. That growth ranks 2 of 8 among the personal care products companies we cover. Free-cash-flow margin rose to 2.3% from -20.9% a year earlier. Operating margin narrowed to 0.8% from 6.2%. The diluted share count is down 3.6% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 7 financial-health checks. Our valuation models combined value is $27.47 a share, against a share price of $28.19.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Edgewell Personal Care Co's trailing-twelve-month revenue grew 11.6% year on year, with a free-cash-flow margin of 2.3%. Where it stands out: revenue growth of 11.6% ranks 3 of 21 personal care products companies we cover. Where it lags: gross margin of 39.5% ranks 18 of 21 personal care products companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 11.6% (+5.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 5.1 points higher than a quarter earlier.
  • Shrinking share count. Diluted shares fell 3.6% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Margins narrowing. Operating margin is down 5.4 points on a year ago.
  • Gross margin slipping. Gross margin is down 3.9 points on a year ago.
  • Below peers: net margin. Net margin of -4.2% ranks 16 of 21 personal care products companies we cover (median 3.4%).
  • Below peers: free-cash-flow margin. Free-cash-flow margin of 2.3% ranks 16 of 21 personal care products companies we cover (median 9.6%).
  • Heavily shorted. 10.4% of the shares available to trade are sold short (8.0 days of average volume to cover).

Latest results: FY2026 Q3

Filed August 5, 2026
Earnings per share
$0.72 against an average estimate of $0.61: beat by 17.6%
Revenue
$570m, up 1.7% on a year earlier
Share reaction
-1.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
reported net sales growth 1.3% to 1.8% (fiscal 2026); adjusted EPS $1.8 to $2 (fiscal 2026)
Next report
November 12, 2026; average EPS estimate $0.77

Edgewell Personal Care's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week+1.9%
  • 1 month+5.6%
  • This year+70.3%
  • 1 year+51.1%
  • 5 years-17.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.2B
Operating margin
0.8%
Net margin
-4.2%
EPS (TTM, diluted)
$-2.00

Growth

Revenue growth
+11.6%
Change in growth rate
+5.1 pts
Share count change
−3.6%

Cash

Free cash flow (TTM)
$52.4M
FCF margin
2.3%
Stock pay % of revenue
0.9%

Earnings

Last results
August 5, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Edgewell Personal Care Co valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Edgewell Personal Care Co as an operating company, with every model that fits that kind of business. Cost of equity 7.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.57 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$16 ~$4.8–$24 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$34 ~$30–$51 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$19 ~$12–$30 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$12 ~$10–$15 Included
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$45 ~$30–$100 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$45 ~$33–$61 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$25 ~$12–$45 6 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Edgewell Personal Care Co with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$71.10$65.06$41.33$29.05$24.93$32.99$34.53$34.63$34.59$19.79$28.47
Market value$4.2bn$3.7bn$2.3bn$1.6bn$1.4bn$1.8bn$1.9bn$1.8bn$1.7bn$942m$1.3bn
+ Net debt (− = net cash)$1.1bn$1.0bn$1.0bn$875m$885m$771m$1.2bn$1.2bn$1.1bn$1.2bn$853m
Enterprise value$5.3bn$4.8bn$3.3bn$2.4bn$2.2bn$2.6bn$3.1bn$2.9bn$2.8bn$2.1bn$2.2bn
Multiples
Price / sales 1.8x1.6x1.0x0.7x0.7x0.9x0.9x0.8x0.8x0.4x0.6x
Price / earnings 23.8xn/m21.8x—20.1x15.5x18.6x15.6x17.6x37.1x—
Price / free cash flow 36.2x15.3x11.4x11.9x7.4x10.6x40.6x——22.8x25.3x
EV / EBITDA ———7.2x8.5x7.9x11.3x9.3x9.8x11.4x25.4x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

44 /100

Weak moat

How hard Edgewell Personal Care's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 1 / 20

    Net income has been a median 2.5% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 44.0%, moving by 2.9 percentage points (standard deviation) across 10 years.

  • Durability 3 / 20

    Operating margin has been a median 9.4%; its worst year was 0.8%.

  • Cash conversion 11 / 20

    Free cash flow was positive in 8 of 10 years, at a median 6.0% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 15.2% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (49 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $480m and EPS of $0.77 (range $0.76 to $0.79) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.93 −24% $2.0bn −10%
Next $1.98 +3% $2.0bn +1%

Next year's EPS estimate has moved −3.9% in 90 days, across 7 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.9% on 90 days ago. In the last 30 days, 5 analysts raised Edgewell Personal Care Co's forecast and 2 cut it.

Consensus EPS forecast Edgewell Personal Care Co, last 90 days
$1.85 $1.90 $1.95 $2.00 $2.05 $2.10 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.89 Current fiscal year, 60 days ago: $1.93 Current fiscal year, 30 days ago: $1.93 Current fiscal year, 7 days ago: $1.93 Current fiscal year, Now: $1.93 $1.93 Next fiscal year, 90 days ago: $2.06 Next fiscal year, 60 days ago: $2.01 Next fiscal year, 30 days ago: $2.01 Next fiscal year, 7 days ago: $1.99 Next fiscal year, Now: $1.98 $1.98

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.89$2.06
60 days ago $1.93$2.01
30 days ago $1.93$2.01
7 days ago $1.93$1.99
Now $1.93$1.98

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.61 $0.72 +17.6%
Mar 2026 $0.44 $0.60 +36.4%
Dec 2025 −$0.16 −$0.16 +1.3%
Sept 2025 $0.81 $0.68 −15.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Reported net sales fiscal 2026 1.3% growth to 1.8% growth GAAP Narrowed
    “Reported net sales are now expected to increase in the range of approximately 1.3% to 1.8% (previously increase 0.8% to 3.8%)” source
  • Adjusted EPS fiscal 2026 $1.80 to $2.00 Non-GAAP Narrowed
    “Adjusted EPS is expected to be in the range of $1.80 to $2.00 (previously $1.70 to $2.10)” source
  • Adjusted EBITDA fiscal 2026 $250m to $260m Non-GAAP Narrowed
    “Adjusted EBITDA is expected to be in the range of $250 to $260 million (previously $245 to $265 million)” source
  • Other income/expense, net fiscal 2026 about $26m Raised
    “Other income/expense, net is expected to be approximately $26 million income, (previously $21 million income)” source
  • Interest expense associated with debt fiscal 2026 about $70m
    “Interest expense associated with debt is expected to be approximately $70 million” source
  • Adjusted effective tax rate fiscal 2026 22% to 23% Non-GAAP
    “Adjusted effective tax rate is expected to be approximately 22% to 23%” source
Show 4 more items
  • Capital expenditures (% of net sales) fiscal 2026 3% to 3.5%
    “Capital expenditures are expected to be in the range of approximately 3.0% to 3.5% of net sales” source
  • Adjusted free cash flow fiscal 2026 $80m to $110m Non-GAAP
    “Adjusted free cash flow is expected to be approximately $80 to $110 million” source
  • Pre-tax restructuring and repositioning charges full fiscal year about $92m GAAP Raised
    “As a result of these actions, the Company expects to incur pre-tax charges of approximately $92 million (previously $90 million) for the full fiscal year.” source
  • Adjusted net debt leverage fiscal year end 2026 3.3 to 3.4 Non-GAAP Narrowed
    “Adjusted net debt leverage is expected to be approximately in the range of 3.3x to 3.4x at fiscal year end (previously in the range of 3.3x to 3.5x)” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

7 analysts, Nov 2026
Buy343%
Hold457%
Sell00%

Monthly trend

  1. Nov 20261247
  2. Oct 20261247
  3. Sep 20261247

Counts of recommendations published by analysts covering Edgewell Personal Care Co, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.4%
of tradable shares
Days to cover
7.98
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
6,700
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +51.1%

$18.85 on October 31, 2025 to $28.47

ThenNowEffect
Revenue (last 12 months) $2.0bn $2.2bn +11.6%
P/S multiple 0.5x 0.6x +30.4%
Share count 48m 47m +3.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −16.0%

$33.90 on November 3, 2023 to $28.47

ThenNowEffect
Revenue (last 12 months) $2.3bn $2.2bn −0.5%
P/S multiple 0.8x 0.6x −24.2%
Share count 52m 47m +11.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
EPC+34%−14%−4%−7%−48%+70%
Industry peers (median)+31%−33%+6%−11%−34%−1%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
EPC42%50%33%58%8%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
EPC−26%−37%−24%−18%−53%−33%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 80% from July 8, 2016 to December 8, 2025. Getting back needed a 402% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$15.60 – $29.50
From 52-week high
−3.5%
vs 50-day average
+2.5%
vs 200-day average
+19.8%
Volatility (1 year)
43%
Beta vs S&P 500
0.17

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±4.8%
After a week
5 up, 7 down
typical move ±6.4%
After a month
5 up, 7 down
typical move ±4.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −1.4% −0.4% +0.5% −0.1%
May 6, 2026 −5.2% +1.1% −20.2% −13.0%
February 9, 2026 −1.2% +0.2% +6.5% −3.3%
November 13, 2025 −4.1% −1.7% −10.0% −6.6%
August 5, 2025 −13.1% +0.3% −9.9% −5.1%
May 7, 2025 −9.4% +1.1% −6.7% −9.4%
February 10, 2025 −9.5% +0.8% −5.3% −2.1%
November 7, 2024 −0.5% +1.2% −3.8% +2.5%
August 6, 2024 −0.2% +0.2% −1.9% +6.2%
May 8, 2024 +4.4% +0.6% +7.5% +3.8%
February 7, 2024 +5.6% +0.9% +4.1% +3.2%
November 9, 2023 −2.5% +0.8% +0.7% +0.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Edgewell Personal Care Co in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Edgewell Personal Care Co
$2B $2.1B $2.2B $2.3B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $2.3B Revenue (TTM), FY24 Q1: $2.3B Revenue (TTM), FY24 Q2: $2.3B Revenue (TTM), FY24 Q3: $2.3B Revenue (TTM), FY24 Q4: $2.3B Revenue (TTM), FY25 Q1: $2.2B Revenue (TTM), FY25 Q2: $2.1B Revenue (TTM), FY25 Q3: $2B Revenue (TTM), FY25 Q4: $2.2B Revenue (TTM), FY26 Q1: $2.2B Revenue (TTM), FY26 Q2: $2.2B Revenue (TTM), FY26 Q3: $2.2B $2.2B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $2.3B
FY24 Q1 $2.3B
FY24 Q2 $2.3B
FY24 Q3 $2.3B
FY24 Q4 $2.3B
FY25 Q1 $2.2B
FY25 Q2 $2.1B
FY25 Q3 $2B
FY25 Q4 $2.2B
FY26 Q1 $2.2B
FY26 Q2 $2.2B
FY26 Q3 $2.2B
Revenue growth, TTM YoY Edgewell Personal Care Co
-20% -10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 3.7% Revenue growth, TTM YoY, FY24 Q1: 4.3% Revenue growth, TTM YoY, FY24 Q2: 2.0% Revenue growth, TTM YoY, FY24 Q3: 0.7% Revenue growth, TTM YoY, FY24 Q4: 0.1% Revenue growth, TTM YoY, FY25 Q1: -4.0% Revenue growth, TTM YoY, FY25 Q2: -7.7% Revenue growth, TTM YoY, FY25 Q3: -11.5% Revenue growth, TTM YoY, FY25 Q4: -1.3% Revenue growth, TTM YoY, FY26 Q1: 2.4% Revenue growth, TTM YoY, FY26 Q2: 6.5% Revenue growth, TTM YoY, FY26 Q3: 11.6% 11.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 3.7%
FY24 Q1 4.3%
FY24 Q2 2.0%
FY24 Q3 0.7%
FY24 Q4 0.1%
FY25 Q1 -4.0%
FY25 Q2 -7.7%
FY25 Q3 -11.5%
FY25 Q4 -1.3%
FY26 Q1 2.4%
FY26 Q2 6.5%
FY26 Q3 11.6%
Operating margin (TTM) Edgewell Personal Care Co
0% 5% 10% 15% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 10.1% Operating margin (TTM), FY24 Q1: 9.7% Operating margin (TTM), FY24 Q2: 10.3% Operating margin (TTM), FY24 Q3: 10.2% Operating margin (TTM), FY24 Q4: 8.8% Operating margin (TTM), FY25 Q1: 8.4% Operating margin (TTM), FY25 Q2: 7.7% Operating margin (TTM), FY25 Q3: 6.2% Operating margin (TTM), FY25 Q4: 4.3% Operating margin (TTM), FY26 Q1: 3.1% Operating margin (TTM), FY26 Q2: 1.7% Operating margin (TTM), FY26 Q3: 0.8% 0.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 10.1%
FY24 Q1 9.7%
FY24 Q2 10.3%
FY24 Q3 10.2%
FY24 Q4 8.8%
FY25 Q1 8.4%
FY25 Q2 7.7%
FY25 Q3 6.2%
FY25 Q4 4.3%
FY26 Q1 3.1%
FY26 Q2 1.7%
FY26 Q3 0.8%
FCF margin (TTM) Edgewell Personal Care Co
-30% -20% -10% 0% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -11.8% FCF margin (TTM), FY24 Q1: -10.9% FCF margin (TTM), FY24 Q2: -9.3% FCF margin (TTM), FY24 Q3: -12.2% FCF margin (TTM), FY24 Q4: -12.8% FCF margin (TTM), FY25 Q1: -15.6% FCF margin (TTM), FY25 Q2: -20.5% FCF margin (TTM), FY25 Q3: -20.9% FCF margin (TTM), FY25 Q4: 1.9% FCF margin (TTM), FY26 Q1: 1.6% FCF margin (TTM), FY26 Q2: 2.2% FCF margin (TTM), FY26 Q3: 2.3% 2.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -11.8%
FY24 Q1 -10.9%
FY24 Q2 -9.3%
FY24 Q3 -12.2%
FY24 Q4 -12.8%
FY25 Q1 -15.6%
FY25 Q2 -20.5%
FY25 Q3 -20.9%
FY25 Q4 1.9%
FY26 Q1 1.6%
FY26 Q2 2.2%
FY26 Q3 2.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Edgewell Personal Care took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $2.2B
  2. Cost of revenue $1.3B · 58.4%
  3. Gross profit $925M · 41.6%
  4. Research and development $57.6M · 2.6%
  5. Selling, general and admin $425M · 19.1%
  6. Other operating costs $346M · 15.5%
  7. Operating income $96.6M · 4.3%
  8. Interest and other $71.2M · 3.2%
  9. Net income $25.4M · 1.1%

Shares of revenue. Source: Edgewell Personal Care's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Sept 2009 2010 Sept 2010 2011 Sept 2011 2012 Sept 2012 2013 Sept 2013 2014 Sept 2014 2015 Sept 2015 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 4,000 4,248 4,646 4,567 2,449 2,612 2,421 2,362 2,298 2,234 2,141 1,950 2,087 2,172 2,252 2,254 2,224 2,244
Gross profit 1,859 2,019 2,146 2,138 1,199 1,290 1,184 1,160 1,126 1,033 967 881 951 881 941 956 925 886
EBITDA — — — — — — — — — — 338 265 327 272 318 287 185 86
Operating income — — — — — — — — — — 244 176 240 182 227 199 97 18
Net income 298 403 261 409 407 356 −275 179 6 103 −372 68 118 100 115 99 25 −93
Diluted EPS $4.72 $5.72 $3.72 $6.22 $6.47 $5.69 −$4.44 $2.99 $0.10 $1.90 −$6.88 $1.24 $2.13 $1.85 $2.21 $1.97 $0.53 −$2.00
Growth (year on year)
Revenue −7.6% +6.2% +9.4% −1.7% −46.4% +6.7% −7.3% −2.4% −2.7% −2.8% −4.2% −8.9% +7.1% +4.0% +3.7% +0.1% −1.3% +11.6%
EBITDA — — — — — — — — — — — −21.6% +23.5% −16.8% +17.0% −9.8% −35.5% −54.6%
Operating income — — — — — — — — — — — −27.8% +36.3% −24.0% +24.5% −12.2% −51.5% −85.5%
Net income −9.6% +35.3% −35.2% +56.5% −0.5% −12.5% −177.3% — −96.8% — −460.3% — +74.3% −15.5% +15.3% −14.0% −74.2% −243.8%
Diluted EPS −15.6% +21.2% −35.0% +67.2% +4.0% −12.1% −178.0% — −96.7% — −462.1% — +71.8% −13.1% +19.5% −10.9% −73.1% −249.2%
Margins
Gross margin 46.5% 47.5% 46.2% 46.8% 49.0% 49.4% 48.9% 49.1% 49.0% 46.2% 45.1% 45.2% 45.6% 40.5% 41.8% 42.4% 41.6% 39.5%
EBITDA margin — — — — — — — — — — 15.8% 13.6% 15.7% 12.5% 14.1% 12.7% 8.3% 3.8%
Operating margin — — — — — — — — — — 11.4% 9.0% 11.5% 8.4% 10.1% 8.8% 4.3% 0.8%
Net margin 7.4% 9.5% 5.6% 9.0% 16.6% 13.6% −11.4% 7.6% 0.2% 4.6% −17.4% 3.5% 5.6% 4.6% 5.1% 4.4% 1.1% −4.2%
Free-cash-flow margin 8.7% 12.8% 6.8% 11.4% 26.9% 18.6% 2.0% 5.0% 10.6% 8.8% 6.2% 9.5% 8.2% 2.1% −11.8% −12.8% 1.9% 2.3%
Cash flow
Cash from operations 489 652 413 632 750 572 149 187 314 259 191 233 229 102 −216 −231 118 121
Capital spending 140 109 98 111 91 85 99 70 69 62 58 48 57 56 50 57 77 69
Free cash flow 350 544 315 521 659 487 49 117 245 197 133 185 172 46 −266 −288 41 52
Stock-based pay — 28 37 45 33 30 33 26 22 17 18 19 27 24 28 27 25 20
Free cash flow after stock pay — 516 277 476 626 457 17 92 222 180 115 166 145 22 −293 −314 17 32
Balance sheet
Cash 359 630 471 719 998 1,129 712 739 503 266 342 365 479 189 216 209 226 397
Total debt 2,390 2,289 2,369 2,533 2,238 2,288 1,722 1,826 1,525 1,292 1,217 1,250 1,250 1,405 1,372 1,284 1,390 1,250
Net debt (negative = net cash) 2,030 1,659 1,897 1,814 1,240 1,159 1,009 1,087 1,023 1,026 875 885 771 1,216 1,156 1,075 1,164 853
Diluted shares 63m 71m 70m 66m 63m 63m 62m 60m 58m 55m 54m 55m 55m 54m 52m 50m 48m 47m
Returned to shareholders
Dividends — 0 0 25 106 124 93 0 0 — 0 0 26 33 32 31 29 28
Buybacks 0 0 276 418 0 94 175 197 165 124 0 0 9 125 75 59 90 16
Total returned 0 0 276 443 106 218 268 197 165 124 0 0 35 158 107 89 120 44

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $3.5bn
Short-term assets $1.1bnLonger-term assets $2.4bn
What it owes, and who funded it · $3.5bn
Short-term liabilities $604mLonger-term liabilities $1.5bnShareholders' equity $1.5bn
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $604m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $1.5bn of longer-dated liabilities.
  • More cash than debt $397m of cash against $1.2bn of debt.
  • Debt below 40% of shareholders' equity Debt is 85% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 92% to 85% over five years.
  • A year's operating cash flow covers at least 20% of debt $121m of operating cash flow against $1.2bn of debt.
  • Operating profit covers interest at least five times over Operating income of $18m against $69m of interest.

From Edgewell Personal Care Co's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$15.8M
Dividends (TTM)
$28.4M
Returned to shareholders
84%
of free cash flow
Buybacks, last 3 fiscal years
$224M
Diluted share count
−3.6%
year over year
Total shareholder yield
3.4%
dividends 2.2% + buybacks 1.2% of market value
R&D spending
2.6%
of revenue
Sales & admin spending
19.8%
of revenue
Days sales outstanding
19 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in personal care products
Last 12 months unless stated EPC BRBR ELF IPAR NUS HLF Median
Revenue, last 12 months $2.2bn $2.4bn $1.8bn $1.5bn $1.4bn $5.3bn $913m
Revenue growth, last 12 months 11.6% 5.9% 31.2% 2.9% −15.4% 6.4% 3.5%
Revenue growth, 3-year average −0.2% 14.4% 37.9% 7.4% −12.3% 1.6% −0.1%
Revenue growth, latest quarter 1.7% 4.2% 35.5% 2.1% −17.1% 6.0% 2.7%
Gross margin 39.5% 28.6% 74.4% 63.8% 69.2% 77.6% 69.2%
Operating margin 0.8% 13.3% 7.2% 17.3% −0.8% 9.6% 6.7%
Operating margin, 3-year average 5.7% 16.1% 10.4% 17.9% −2.8% 8.7% 5.5%
Net margin −4.2% 7.3% 3.4% 11.2% −15.7% 3.4% 3.4%
Cash from operations / revenue 5.4% 9.9% 16.9% 17.1% 3.7% 7.5% 9.9%
Free-cash-flow margin 2.3% 9.6% 15.9% 16.4% 0.8% 6.4% 9.6%
Free-cash-flow margin, 3-year average −10.2% 9.3% 9.8% 11.7% 3.4% 4.8% 6.0%
Stock pay / revenue 0.9% 1.0% 5.5% 0.1% 1.0% 0.8% 1.0%
Change in share count −3.6% −7.9% 3.0% −0.0% 0.1% 3.3% −0.0%

Median of all 21 companies we cover in personal care products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

21 personal care products companies
Measure Company Peer median Rank
Revenue growth Growth 11.6% 3.5% 3 of 21
Change in growth rate Growth +5.1pp +0.7pp 5 of 21
Gross margin Profitability 39.5% 69.2% 18 of 21
Operating margin Profitability 0.8% 6.7% 15 of 21
Net margin Profitability -4.2% 3.4% 16 of 21
Free-cash-flow margin Cash generation 2.3% 9.6% 16 of 21
Stock pay as % of revenue Cash generation 0.9% 1.0% 8 of 18
Long-term debt as % of assets Balance sheet 35.2% 29.7% 10 of 13
Change in share count Balance sheet -3.6% -0.0% 5 of 19
Days sales outstanding Balance sheet 19 days 33 days 6 of 14

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to September 30, 2025
Segments
Line of business Revenue Share YoY
Wet Shave $1.2B 54.8% ▼ 0.8%
Sun and Skin Care $743M 33.4% ▲ 0.3%
Feminine Care $262M 11.8% ▼ 7.8%
Products and services
Line of business Revenue Share YoY
Razorsandblades $1.1B 49.7% ▼ 0.6%
Suncareproducts $459M 20.6% ▼ 5.1%
Tampons Pads and Liners $262M 11.8% ▼ 7.8%
Infant Care and Other Products $201M 9.0% ▲ 9.7%
Shavinggelsandcreams $114M 5.1% ▼ 3.5%
Skin Care Products $83.6M 3.8% ▲ 12.5%
Geography
Region Revenue Share YoY
United States $1.2B 54.2% ▼ 4.6%
Outside the US $1B 45.8% ▲ 2.8%

From Edgewell Personal Care Co's 10-K filed November 18, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.4B
Institutions reporting
223
Shares held vs prior quarter
▲ 3.0%
Positions opened / closed
30 / 27

Top buyers and sellers, Q2 2026: 101 institutions bought and 107 sold ; the biggest buyer was American Century Companies Inc (+1.2M shares) and the biggest seller Millennium Management LLC (−638K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $198M 7.4M 13.6% ▼ 0.1%
Brandes Investment Partners, LP $190M 7.1M 13.1% ▲ 5.0%
American Century Companies Inc $145M 5.4M 10.0% ▲ 27.4%
Rubric Capital Management LP $95.2M 3.5M 6.6% ▼ 11.4%
Vanguard Portfolio Management LLC $82.1M 3.1M 5.7% ▲ 4.3%
Vanguard Capital Management LLC $54.9M 2.0M 3.8% ▲ 0.3%
State Street Corp $50M 1.9M 3.5% ▲ 4.9%
Dimensional Fund Advisors LP $49.9M 1.9M 3.4% ▼ 23.9%
Two Sigma Investments, LP $39.7M 1.5M 2.7% ▲ 21.4%
LSV Asset Management $36.9M 1.4M 2.6% ▲ 13.5%
Woodline Partners LP $32.5M 1.2M 2.2% ▲ 72.9%
Geode Capital Management, LLC $32.5M 1.2M 2.2% ▲ 7.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Edgewell Personal Care Co's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5,731 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $5,731 net selling
Insider Date Trade Shares Price Value
Dunham John M Chief Accounting Officer November 20, 2025 Sell 333 $17.21 $5,731

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 9, 2026
  • November 13, 2025
  • August 5, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Edgewell Personal Care Co was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Edgewell Personal Care Co in brief

What does Edgewell Personal Care Co do?
Edgewell Personal Care Co is a US-listed company in the personal care products industry. Its financial year ends in September.
What is Edgewell Personal Care Co's stock ticker?
Edgewell Personal Care Co trades under the ticker EPC on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Edgewell Personal Care Co's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Edgewell Personal Care Co reported revenue of $2.2B, 11.6% higher than a year earlier, according to its SEC filings.
What is Edgewell Personal Care Co's free cash flow?
Edgewell Personal Care Co's free-cash-flow margin is 2.3% of revenue over the trailing twelve months, ranking 16 of the 21 personal care products companies we cover.
Who are Edgewell Personal Care Co's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Brandes Investment Partners, LP and American Century Companies Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Edgewell Personal Care Co buying back stock, and does it pay a dividend?
Edgewell Personal Care Co spent $15.8M on share repurchases over the trailing twelve months, and its diluted share count fell 3.6% over the year.
What is Edgewell Personal Care Co's market cap?
On November 2, 2026, Edgewell Personal Care Co's market capitalisation was about $1.3B and net debt of $853M. Market figures come from third-party market data and may be delayed.
Does Edgewell Personal Care Co pay a dividend?
Yes: Edgewell Personal Care Co paid $28.4M in dividends over the trailing twelve months, a dividend yield of 2.16%.
How much debt does Edgewell Personal Care Co have?
Edgewell Personal Care Co's debt-to-equity ratio is 85.3%, from its latest balance sheet (92.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Edgewell Personal Care Co's competitors?
In our Personal Care Products peer group, the companies closest to Edgewell Personal Care Co are Bellring Brands, Inc., E.l.f. Beauty, Inc., Interparfums Inc, NU Skin Enterprises, Inc. and Herbalife LTD. The side-by-side comparison below sets their revenue, margins and growth against Edgewell Personal Care Co's.
Are insiders buying or selling Edgewell Personal Care Co stock?
Over the last 12 months, Edgewell Personal Care Co's directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Edgewell Personal Care Co's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Edgewell Personal Care Co announces its own schedule.